Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001144204-17-048729
Filing Date
2017-09-19
Accepted
2017-09-19 18:29:31
Documents
1
Period of Report
2017-09-15

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT v475387_4.html 4  
1 OWNERSHIP DOCUMENT v475387_4.xml 4 3849
  Complete submission text file 0001144204-17-048729.txt   5270
Mailing Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080
Business Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 6502444990
TITAN PHARMACEUTICALS INC (Issuer) CIK: 0000910267 (see all company filings)

EIN.: 943171940 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O CELGENE CORPORATION 86 MORRIS AVENUE SUMMIT NJ 07901
Business Address
Smith Scott Andrew (Reporting) CIK: 0001614975 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-13341 | Film No.: 171092938